US Stock MarketDetailed Quotes
PYPD PolyPid
- 2.8715
- +0.3715+14.86%
Close Dec 18 16:00 ET
19.54MMarket Cap-0.11P/E (TTM)
2.9750High2.5202Low19.09KVolume2.5900Open2.5000Pre Close50.94KTurnover0.53%Turnover RatioLossP/E (Static)6.80MShares9.200052wk High9.06P/B10.34MFloat Cap2.370052wk Low--Dividend TTM3.60MShs Float583.5000Historical High--Div YieldTTM18.19%Amplitude2.3700Historical Low2.6680Avg Price1Lot Size
PolyPid Stock Forum
Sign in to post a comment
$ABVC BioPharma (ABVC.US)$ - Progress continues in our ADHD program with Phase IIb trials at multiple prominent sites. We aim to have an interim report by Q4 2024. ABV-1601 for MDD in cancer patients has completed Phase I study preparation, including the Site Initiation Visit (SIV). The study is set to initiate by the end of 2024.
$Ascent Solar Technologies (ASTI.US)$- Following delivery and the successful completion of the on-orbi...
$Ascent Solar Technologies (ASTI.US)$- Following delivery and the successful completion of the on-orbi...
25
7
7
$PolyPid (PYPD.US)$
PolyPid Announces Research and Development Collaboration with ImmunoGenesis Leveraging PLEX Technology to Enhance Cancer Immunotherapy
Wednesday, 11th December at 7:00 am
PETACH TIKVA, Israel, Dec. 11, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced a new research and development collaboration with ImmunoGenesis, Inc. ("ImmunoGenesis"), a Houston-based cli...
PolyPid Announces Research and Development Collaboration with ImmunoGenesis Leveraging PLEX Technology to Enhance Cancer Immunotherapy
Wednesday, 11th December at 7:00 am
PETACH TIKVA, Israel, Dec. 11, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced a new research and development collaboration with ImmunoGenesis, Inc. ("ImmunoGenesis"), a Houston-based cli...
$PolyPid (PYPD.US)$ Reuters· just
PolyPid Announces Research and Development Collaboration With Immunogenesis Leveraging Plex Technology to Enhance Cancer Immunotherapy
PolyPid Announces Research and Development Collaboration With Immunogenesis Leveraging Plex Technology to Enhance Cancer Immunotherapy
$PolyPid (PYPD.US)$ Approximately 250 Patients of a Planned Total of 600 Subjects Currently Enrolled in SHIELD II
Unblinded Interim Analysis to be Conducted Once Approximately 400 PatientsComplete Their 30-Day Follow-up; Top-line Results Expected in the First Quarter of 2025
Unblinded Interim Analysis to be Conducted Once Approximately 400 PatientsComplete Their 30-Day Follow-up; Top-line Results Expected in the First Quarter of 2025
$PolyPid (PYPD.US)$
NEWS
PolyPid Announces Enrollment of 200th Patient in Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections
NEWS
PolyPid Announces Enrollment of 200th Patient in Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections
1
1
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
$PolyPid (PYPD.US)$ 1-30 R/S tomorrow!
No comment yet
Heat List
US
Overall
Symbol
Price
% Chg
No Data
AddiBee0925 : Hey Jag. Just a heads up. If all goes as planned, the launch for SIDU and SpaceX is on the schedule for this Friday on the 20th. I wouldn't think that it would be rescheduled so soon to the launch, at least no report has said otherwise.
Jaguar8 OP AddiBee0925 : Yes. But there might be a build up of the price before the launch just like LUNR. Hopefully it goes well.
AddiBee0925 Jaguar8 OP : yeah I'm thinking the same
Jaguar8 OP browny_440 : TNXP will be good if FDA releases decision soon
72306783 : I would like to ask, what signals or standards do you use to start building positions? I am still learning... Thank you very much for your Share
View more comments...